Modulation of CCL2 signaling by CCR-2B antagonists and CCL2-blocking antibodies in an experimental model of RA showed beneficial effects on inflammation and joint destruction (Dawson et al., 2003). Here, CCR2 is linked to rheumatoid arthritis.